Exposure to Azathioprine Metabolites and Clinical Outcome in Indian Patients with Crohn’s Disease

ABSTRACT

Aim: To determine the concentration of 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP), the interpatient variability, and the relationship with disease activity in patients with Chron’s disease on long-term stable doses of azathioprine (AZA). Methods: This is a prospective, tertiary care single-center hospital study in adult Chron’s disease patients treated with AZA. The quantification of phenotypic thiopurine methyltransferase enzyme activity in red blood cells and the estimation of the concentration of 6-TGN and 6-MMP in whole blood was performed using the HPLC-UV detector method. A clinical response was categorized as remission (Harvey-Bradshaw Index [HBI] < 5) or improvement (drop from baseline of at least three points of HBI) based on HBI. Exposure to metabolite concentrations and the clinical response to AZA treatment was observed. Results: Study analysis included 30 patients who were initiated on AZA, and they were followed up with an estimation of metabolite concentrations to determine their clinical outcome. At six months, 93% of (n = 28) patients continued to be on AZA and had clinical improvement. All the patients achieved remission of Chron’s disease. Only two patients developed adverse effects such as joint pain and thrombocytopenia. Conclusion: AZA is a safe and effective therapy in managing Chron’s disease when administered after determining thiopurine methyltransferase phenotype and with dose optimization performed using therapeutic drug monitoring of 6-TGN and 6-MMP.

KEYWORDS

• Azathioprine
• Crohn’s disease
• TPMT phenotype
• 6-TGN
• 6-MMP

Showing references and in-text citations exactly as published.

• DOI10.1177/0976500X221085804Copy

RELATED ARTICLES

Matched on section and article type within this issue of JPP.

• Article · VOLUME 13, ISSUE 3A Prospective, Observational Study of the Spontaneous Reporting Patterns of Adverse Drug Reactions in a Tertiary Care Teaching HospitalSanthosh Kumar Raju, Geetha S., Shobha Kamble · pp. 272–277Research ArticleSame type: Article
• Article · VOLUME 13, ISSUE 3The Effect of Intravenous Ketamine After Spinal Anesthesia on the Duration of Postoperative Analgesia and Analgesic RequirementAparna Bagle, Spoorti Pujari, Krusha Shah, Shreyank Solanki, Chandrakala Singh · pp. 278–283Research ArticleSame type: Article
• Article · VOLUME 13, ISSUE 3Homocysteine Levels and Clinical Outcomes in Schizophrenia—A Pilot Randomized Controlled TrialVenkata Aksheena Varahi Vedam, Mohan Krishna Ghanta, Suvarna Jyothi Kantipudi, Darling Chellathai David, Melanathuru Vijayalakshmi, Poojith Nuthalapati · pp. 284–292Research ArticleSame type: Article
• Article · VOLUME 13, ISSUE 3Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed VaccinesKatharigatta N. Venugopala · pp. 293–299Same type: Article